THERADIAG Signs a Partnership Agreement for Monitoring of Remicade®

Regulatory News:

THERADIAG (Paris:ALTER) (ISIN code: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans) a company specialized in in vitro diagnostics and theranostics, today announced that it had signed a partnership with MSD France (Merck Sharp & Dohme) to supply its LISA TRACKER® kits for the monitoring of Remicade®.

"This new agreement follows other recently announced partnerships, and positions Theradiag as the preferred supplier for pharmaceuticals companies offering infliximab. Being able to build on strategic partnerships such as those with MSD, Biogen, Pfizer and Miraca Life Sciences is an essential factor in supporting our growth and building our reputation, both in France and internationally,” commented Michel Finance, Theradiag’s Chief Executive Officer.

Under this agreement, MSD France has referenced the LISA TRACKER® monitoring kits to accompany the supply of Remicade®. Kits will be supplied under the conditions set out in the contracts to supply Remicade® won by MSD France.

Theradiag will also be responsible for implementation, training in the use of the kits by laboratories and follow-up on monitoring-related requests from clinicians.

A global pharmaceutical laboratory driven by research, MSD provides innovative solutions that improve the quality of life for millions of patients in France and around the world. Active in France since 1961, MSD France is a subsidiary of US company Merck & Co. of Kenilworth, NJ, USA, one of the world’s leading pharmaceutical companies, which invents and develops medicines and vaccines targeting some of the most significant health challenges. MSD’s goal is to provide patients and healthcare professionals with an innovative global health offering, consisting not only of medicines – mainly in the five major therapeutic areas of cardio-metabolism, vaccines, oncology, hospital care and immunology – but also solutions and services, particularly in the digital realm.

About Theradiag

Capitalizing on its expertise in the distribution, development and manufacturing of in vitro diagnostic tests, Theradiag innovates and develops theranostics tests (combining treatment and diagnosis) that measure the efficiency of biotherapies in the treatment of autoimmune diseases, cancer and AIDS. Theradiag is thus participating in the development of customized treatment, which favors the individualization of treatments, the evaluation of their efficacy and the prevention of drug resistance. Theradiag notably markets the Lisa Tracker® range (CE marked), which is a comprehensive multiparameter theranostic solution for patients with autoimmune diseases treated with biotherapies. The Company is based in Marne-la-Vallée, near Paris, and has 70 employees.
For more information about Theradiag, please visit our website: www.theradiag.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20171221005384/en/